Pancreatic Adenocarcinoma, Version 2.2014

Margaret A. Tempero; Mokenge P. Malafa; Stephen W. Behrman; Al B. Benson; Ephraim S. Casper; E. Gabriela Chiorean; Vincent Chung; Steven J. Cohen; Brian Czito; Anitra Engebretson; Mary Feng; William G. Hawkins; Joseph Herman; John P. Hoffman; Andrew Ko; Srinadh Komanduri; Albert Koong; Andrew M. Lowy; Wen Wee Ma; Nipun B. Merchant; Sean J. Mulvihill; Peter Muscarella; Eric K. Nakakura; Jorge Obando; Martha B. Pitman; Sushanth Reddy; Aaron R. Sasson; Sarah P. Thayer; Colin D. Weekes; Robert A. Wolff; Brian M. Wolpin; Jennifer L. Burns; Deborah A. Freedman-Cass

doi:10.6004/jnccn.2014.0106

Pancreatic Adenocarcinoma, Version 2.2014

Margaret A. Tempero
, Mokenge P. Malafa
, Stephen W. Behrman
, Al B. Benson
, Ephraim S. Casper
, E. Gabriela Chiorean
, Vincent Chung
, Steven J. Cohen
, Brian Czito
, Anitra Engebretson
, Mary Feng
, William G. Hawkins
, Joseph Herman
, John P. Hoffman
, Andrew Ko
, Srinadh Komanduri
, Albert Koong
, Andrew M. Lowy
, Wen Wee Ma
, Nipun B. Merchant

Sean J. Mulvihill, Peter Muscarella, Eric K. Nakakura, Jorge Obando, Martha B. Pitman, Sushanth Reddy, Aaron R. Sasson, Sarah P. Thayer, Colin D. Weekes, Robert A. Wolff, Brian M. Wolpin, Jennifer L. Burns, Deborah A. Freedman-Cass

University of California at San Francisco
Moffitt Cancer Center
University of Tennessee Health Science Center
Northwestern University
Memorial Sloan-Kettering Cancer Center
Seattle Cancer Care Alliance
City of Hope National Med Center
Fox Chase Cancer Center
Duke University
Pancreatic Cancer Action Network
University of Michigan, Ann Arbor
Washington University St. Louis
Johns Hopkins University
Stanford University
University of California at San Diego
Roswell Park Cancer Institute
Vanderbilt University
University of Utah
Ohio State University
Massachusetts General Hospital Cancer Center
University of Alabama at Birmingham
University of Colorado Anschutz Medical Campus
University of Texas MD Anderson Cancer Center
Dana-Farber/Brigham and Women's Cancer Center
National Comprehensive Cancer Network

Research output: Contribution to journal › Review article › peer-review

322 Scopus citations

Abstract

The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize major discussion points from the 2014 NCCN Pancreatic Adenocarcinoma Panel meeting. The panel discussion focused mainly on the management of borderline resectable and locally advanced disease. In particular, the panel discussed the definition of borderline resectable disease, role of neoadjuvant therapy in borderline disease, role of chemoradiation in locally advanced disease, and potential role of newer, more active chemotherapy regimens in both settings.

Original language	English
Pages (from-to)	1083-1093
Number of pages	11
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	12
Issue number	8
DOIs	https://doi.org/10.6004/jnccn.2014.0106
State	Published - Aug 1 2014

Access to Document

10.6004/jnccn.2014.0106

Cite this

Tempero, M. A., Malafa, M. P., Behrman, S. W., Benson, A. B., Casper, E. S., Chiorean, E. G., Chung, V., Cohen, S. J., Czito, B., Engebretson, A., Feng, M., Hawkins, W. G., Herman, J., Hoffman, J. P., Ko, A., Komanduri, S., Koong, A., Lowy, A. M., Ma, W. W., ... Freedman-Cass, D. A. (2014). Pancreatic Adenocarcinoma, Version 2.2014. JNCCN Journal of the National Comprehensive Cancer Network, 12(8), 1083-1093. https://doi.org/10.6004/jnccn.2014.0106

@article{5531dcfda52540768ef3dc017d5b120f,

title = "Pancreatic Adenocarcinoma, Version 2.2014",

abstract = "The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize major discussion points from the 2014 NCCN Pancreatic Adenocarcinoma Panel meeting. The panel discussion focused mainly on the management of borderline resectable and locally advanced disease. In particular, the panel discussed the definition of borderline resectable disease, role of neoadjuvant therapy in borderline disease, role of chemoradiation in locally advanced disease, and potential role of newer, more active chemotherapy regimens in both settings.",

author = "Tempero, \{Margaret A.\} and Malafa, \{Mokenge P.\} and Behrman, \{Stephen W.\} and Benson, \{Al B.\} and Casper, \{Ephraim S.\} and Chiorean, \{E. Gabriela\} and Vincent Chung and Cohen, \{Steven J.\} and Brian Czito and Anitra Engebretson and Mary Feng and Hawkins, \{William G.\} and Joseph Herman and Hoffman, \{John P.\} and Andrew Ko and Srinadh Komanduri and Albert Koong and Lowy, \{Andrew M.\} and Ma, \{Wen Wee\} and Merchant, \{Nipun B.\} and Mulvihill, \{Sean J.\} and Peter Muscarella and Nakakura, \{Eric K.\} and Jorge Obando and Pitman, \{Martha B.\} and Sushanth Reddy and Sasson, \{Aaron R.\} and Thayer, \{Sarah P.\} and Weekes, \{Colin D.\} and Wolff, \{Robert A.\} and Wolpin, \{Brian M.\} and Burns, \{Jennifer L.\} and Freedman-Cass, \{Deborah A.\}",

year = "2014",

month = aug,

day = "1",

doi = "10.6004/jnccn.2014.0106",

language = "English",

volume = "12",

pages = "1083--1093",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "8",

}

Tempero, MA, Malafa, MP, Behrman, SW, Benson, AB, Casper, ES, Chiorean, EG, Chung, V, Cohen, SJ, Czito, B, Engebretson, A, Feng, M, Hawkins, WG, Herman, J, Hoffman, JP, Ko, A, Komanduri, S, Koong, A, Lowy, AM, Ma, WW, Merchant, NB, Mulvihill, SJ, Muscarella, P, Nakakura, EK, Obando, J, Pitman, MB, Reddy, S, Sasson, AR, Thayer, SP, Weekes, CD, Wolff, RA, Wolpin, BM, Burns, JL & Freedman-Cass, DA 2014, 'Pancreatic Adenocarcinoma, Version 2.2014', JNCCN Journal of the National Comprehensive Cancer Network, vol. 12, no. 8, pp. 1083-1093. https://doi.org/10.6004/jnccn.2014.0106

TY - JOUR

T1 - Pancreatic Adenocarcinoma, Version 2.2014

AU - Tempero, Margaret A.

AU - Malafa, Mokenge P.

AU - Behrman, Stephen W.

AU - Benson, Al B.

AU - Casper, Ephraim S.

AU - Chiorean, E. Gabriela

AU - Chung, Vincent

AU - Cohen, Steven J.

AU - Czito, Brian

AU - Engebretson, Anitra

AU - Feng, Mary

AU - Hawkins, William G.

AU - Herman, Joseph

AU - Hoffman, John P.

AU - Ko, Andrew

AU - Komanduri, Srinadh

AU - Koong, Albert

AU - Lowy, Andrew M.

AU - Ma, Wen Wee

AU - Merchant, Nipun B.

AU - Mulvihill, Sean J.

AU - Muscarella, Peter

AU - Nakakura, Eric K.

AU - Obando, Jorge

AU - Pitman, Martha B.

AU - Reddy, Sushanth

AU - Sasson, Aaron R.

AU - Thayer, Sarah P.

AU - Weekes, Colin D.

AU - Wolff, Robert A.

AU - Wolpin, Brian M.

AU - Burns, Jennifer L.

AU - Freedman-Cass, Deborah A.

PY - 2014/8/1

Y1 - 2014/8/1

N2 - The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize major discussion points from the 2014 NCCN Pancreatic Adenocarcinoma Panel meeting. The panel discussion focused mainly on the management of borderline resectable and locally advanced disease. In particular, the panel discussed the definition of borderline resectable disease, role of neoadjuvant therapy in borderline disease, role of chemoradiation in locally advanced disease, and potential role of newer, more active chemotherapy regimens in both settings.

AB - The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize major discussion points from the 2014 NCCN Pancreatic Adenocarcinoma Panel meeting. The panel discussion focused mainly on the management of borderline resectable and locally advanced disease. In particular, the panel discussed the definition of borderline resectable disease, role of neoadjuvant therapy in borderline disease, role of chemoradiation in locally advanced disease, and potential role of newer, more active chemotherapy regimens in both settings.

UR - https://www.scopus.com/pages/publications/84906258991

U2 - 10.6004/jnccn.2014.0106

DO - 10.6004/jnccn.2014.0106

M3 - Review article

C2 - 25099441

AN - SCOPUS:84906258991

SN - 1540-1405

VL - 12

SP - 1083

EP - 1093

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 8

ER -

Pancreatic Adenocarcinoma, Version 2.2014

Abstract

Access to Document

Other files and links

Fingerprint

Cite this